

| Technology appraisal (TA) Titles are hyperlinks to full guidance | Date of TA Release (N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed) | Adherence of local formulary to NICE | | | | |
|---|---|--------------------------------------|---------------------------------|--------------------------------------|-----------------------------|---|
| | | Yes (mark 'x' if applicable) | N/A (mark 'x' if applicable) | Date of local decision (DD/MM/YY) | Time to implement (days) | Notes (e.g. Additional stipulations, rationale, method of making available) |
| 2016-17 | | | | | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer [TA439] | 29/03/2017 | X | | 18/04/2017 | 20 | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) [TA434] | 22/03/2017 | | X | 22/03/2017 | 0 | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) [TA435] | 22/03/2017 | | X | 22/03/2017 | 0 | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) [TA436] | 22/03/2017 | | X | 22/03/2017 | 0 | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) [TA437] | 22/03/2017 | | X | 22/03/2017 | 0 | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) [TA438] | 22/03/2017 | | X | 22/03/2017 | 0 | |
| Everolimus for advanced renal cell carcinoma after previous treatment [TA432] | 22/02/2017 | X | | 31/03/2017 | 37 | |
| Apremilast for treating active psoriatic arthritis [TA433] | 22/02/2017 | X | | 20/04/2017 | 57 | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation [TA429] | 25/01/2017 | X | | 31/03/2017 | 65 | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C [TA430] | 25/01/2017 | X | | 15/02/2017 | 21 | |
| Mepolizumab for treating severe refractory eosinophilic asthma [TA431] | 25/01/2017 | X | | 31/03/2017 | 65 | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib [TA427] | 11/01/2017 | X | | 31/03/2017 | 79 | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy [TA428] | 11/01/2017 | X | | 31/03/2017 | 79 | |

| | | | | | | |
|--|------------|---|--|------------|----|--|
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy [TA421] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [TA422] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [TA423] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [TA424] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia [TA425] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia [TA426] | 21/12/2016 | X | | 17/01/2017 | 27 | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction [TA420] | 14/12/2016 | X | | 16/02/2017 | 64 | |
| Nivolumab for previously treated advanced renal cell carcinoma [TA417] | 23/11/2016 | X | | 17/01/2017 | 55 | |
| Dapagliflozin in triple therapy for treating type 2 diabetes [TA418] | 23/11/2016 | X | | 24/11/2016 | 1 | |
| Apremilast for treating moderate to severe plaque psoriasis [TA419] | 23/11/2016 | X | | 19/01/2017 | 57 | |
| Elbasvir–grazoprevir for treating chronic hepatitis C [TA413] | 26/10/2016 | X | | 17/01/2017 | 83 | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [TA414] | 26/10/2016 | X | | 17/01/2017 | 83 | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor [TA415] | 26/10/2016 | X | | 17/01/2017 | 83 | |
| Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer [TA416] | 26/10/2016 | X | | 17/01/2017 | 83 | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [TA406] | 28/09/2016 | X | | 01/11/2016 | 34 | |
| Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [TA407] | 28/09/2016 | X | | 15/12/2016 | 78 | |
| Pegaspargase for treating acute lymphoblastic leukaemia [TA408] | 28/09/2016 | X | | 01/11/2016 | 34 | |

| | | | | | | |
|---|------------|---|--|------------|----|---------------------------------|
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion [TA409] | 28/09/2016 | X | | 01/11/2016 | 34 | |
| Talinogene laherparepvec for treating unresectable metastatic melanoma [TA410] | 28/09/2016 | X | | 01/11/2016 | 34 | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer [TA411] | 28/09/2016 | X | | 28/09/2016 | 0 | Not recommended for use by NICE |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [TA412] | 28/09/2016 | X | | 01/11/2016 | 34 | |
| Bosutinib for previously treated chronic myeloid leukaemia [TA401] | 24/08/2016 | X | | 01/11/2016 | 69 | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin [TA402] | 24/08/2016 | X | | 01/11/2016 | 69 | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer [TA403] | 24/08/2016 | X | | 01/11/2016 | 69 | |
| Degarelix for treating advanced hormone-dependent prostate cancer [TA404] | 24/08/2016 | X | | 20/10/2016 | 57 | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer [TA405] | 24/08/2016 | X | | 01/11/2016 | 69 | |
| Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation [TA398] | 27/07/2016 | X | | 27/07/2016 | 0 | Not recommended for use by NICE |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts [TA399] | 27/07/2016 | X | | 27/07/2016 | 0 | Not recommended for use by NICE |
| Nivolumab in combination with ipilimumab for treating advanced melanoma [TA400] | 27/07/2016 | X | | 24/10/2016 | 89 | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa [TA392] | 22/06/2016 | X | | 19/07/2016 | 27 | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA393] | 22/06/2016 | X | | 15/09/2016 | 85 | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA394] | 22/06/2016 | X | | 15/09/2016 | 85 | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer [TA395] | 22/06/2016 | X | | 19/07/2016 | 27 | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma [TA396] | 22/06/2016 | X | | 19/07/2016 | 27 | |

| | | | | | | |
|---|------------|------------|-----------|------------|-------------------------------|--|
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus [TA397] | 22/06/2016 | X | | 19/07/2016 | 27 | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes [TA390] | 25/05/2016 | X | | 16/06/2016 | 22 | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel [TA391] | 25/05/2016 | X | | 19/07/2016 | 55 | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction [TA388] | 27/04/2016 | X | | 19/05/2016 | 22 | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [TA389] | 26/04/2016 | X | | 19/07/2016 | 84 | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated [TA387] | 26/04/2016 | X | | 19/07/2016 | 84 | |
| | | % "Yes" | % "N/A" | - | Average implement time | |
| Adherence statistics for 2016-17 | | 91% | 9% | | 44 | |